Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) FCF Margin: 2017-2018

Historic FCF Margin for Astria Therapeutics (ATXS) over the last 2 years, with Sep 2018 value amounting to 57,750.00%.

  • Astria Therapeutics' FCF Margin rose 6072280.00% to 57,750.00% in Q3 2018 from the same period last year, while for Sep 2018 it was -15,888.67%, marking a year-over-year change of. This contributed to the annual value of 23,483.00% for FY2018, which is 2886160.00% up from last year.
  • Per Astria Therapeutics' latest filing, its FCF Margin stood at 57,750.00% for Q3 2018, which was up 240.19% from 16,975.76% recorded in Q2 2018.
  • In the past 5 years, Astria Therapeutics' FCF Margin registered a high of 57,750.00% during Q3 2018, and its lowest value of -2,972.80% during Q3 2017.
  • Its 2-year average for FCF Margin is 13,057.57%, with a median of 5,445.64% in 2017.
  • Data for Astria Therapeutics' FCF Margin shows a peak YoY soared of 6,072,280bps (in 2018) over the last 5 years.
  • Quarterly analysis of 2 years shows Astria Therapeutics' FCF Margin stood at -2,254.80% in 2017, then spiked by 6,072,280bps to 57,750.00% in 2018.
  • Its FCF Margin was 57,750.00% in Q3 2018, compared to 16,975.76% in Q2 2018 and 11,963.16% in Q1 2018.